1. Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization
- Author
-
Roberta Bona, Zuleika Michelini, Chiara Mazzei, Alessandra Gallinaro, Andrea Canitano, Martina Borghi, Maria Fenicia Vescio, Antonio Di Virgilio, Maria Franca Pirillo, Mary E. Klotman, Donatella Negri, and Andrea Cara
- Subjects
lentiviral vector ,integrase ,vaccine ,immunization ,human immunodeficiency virus ,simian immunodeficiency virus ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Integrase-defective lentiviral vectors (IDLVs) represent an attractive platform for vaccine development as a result of the ability to induce persistent humoral- and cellular-mediated immune responses against the encoded transgene. Compared with the parental integrating vector, the main advantages for using IDLV are the reduced hazard of insertional mutagenesis and the decreased risk for vector mobilization by wild-type viruses. Here we report on the development and use in the mouse immunogenicity model of simian immunodeficiency virus (SIV)-based IDLV containing a long deletion in the U3 region and with the 3′ polypurine tract (PPT) removed from the transfer vector for improving safety and/or efficacy. Results show that a safer extended deletion of U3 sequences did not modify integrase-mediated or -independent integration efficiency. Interestingly, 3′ PPT deletion impaired integrase-mediated integration but did not reduce illegitimate, integrase-independent integration efficiency, contrary to what was previously reported in the HIV system. Importantly, although the extended deletion in the U3 did not affect expression or immunogenicity from IDLV, deletion of 3′ PPT considerably reduced both expression and immunogenicity of IDLV.
- Published
- 2021
- Full Text
- View/download PDF